Predictors of infection in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 46, Issue 9, 2002, Pages 2294-2300

  Doran, Michele F ^a   Crowson, Cynthia S ^b   Pond, Gregory R ^b   O'Fallon, W Michael ^b   Gabriel, Sherine E ^b  

^a BEAUMONT HOSPITAL   (Ireland)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ADULT; AGE; ARTICLE; CHRONIC LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADRENAL CORTEX HORMONES; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; FORECASTING; HOSPITALIZATION; HUMANS; INCIDENCE; INFECTION; MALE; MIDDLE AGED; MINNESOTA; RISK FACTORS;

EID: 0036745010     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10529     Document Type: Article

References (28)

1. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
2. Gershon S, Wise RP, Niu M, Siegel J. Postlicensure reports of infection during use of etanercept and infliximab [abstract]. Arthritis Rheum 2000;43:S2857.
3. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
4. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? [see comments]. Arthritis Rheum (Arthritis Care Res) 2002;47:17-21.
5. Kaandorp CJE, van Schaardenburg D, Krijnen P, Habbema JDF, van de Laar MAFJ. Risk factors for septic arthritis in patients with joint disease: a prospective study. Arthritis Rheum 1995;38:1819-25.
6. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
7. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
8. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am 1981;245:54-63.
9. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.
11. Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci U S A 1998;95:14447-52.
12. Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000;97:9203-8.
13. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Primary care: infections in patients with diabetes mellitus. N Engl J Med 1999;341:1906-12.
14. Farr BM, Woodhead MA, Macfarlane JT, Bartlett CL, McCraken JS, Wadsworth J, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000;94:422-7.
15. Fernandez-Sola J, Junque A, Estruch R, Monforte R, Torres A, Urbano-Marquez A. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med 1995;155:1649-54.
16. Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999;14:227-36.
17. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
18. Van Albada-Kuipers GA, Linthorst J, Peeters EAJ, Breedveld FC, Dijkmans BAC, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988;31:667-71.
19. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978;21:37-44.
20. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
21. Van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53:224-8.
22. Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
23. Andersen PA, West SG, Nordstrom DM. Toxicity of chronic therapy with pulse methotrexate in rheumatoid arthritis: potential increased risk of infection [abstract]. Arthritis Rheum 1987;30 Suppl 4:S60.
24. Singh G, Ramey DR, Rausch PL, Schettler JD. Serious infections in rheumatoid arthritis: relationship to immunosuppressant use [abstract]. Arthritis Rheum 1999;42 Suppl 9:S242.
25. Boerbooms AMT, Kerstens PJSM, van Loenhout JWA, Mulder J, van de Putte LBA. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
26. Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997;23:219-37.
27. Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997;23:955-67.
28. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.